A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Lemborexant (DAYVIGO)

Orexin Receptor Antagonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2020-04-07
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$32.5M in CY2024 Part D spend89K claims · 25K beneficiaries · 329 plans surveyed

Lowest NADAC
$11.57/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$11.58
Across all dosage forms in distribution.
Highest NADAC
$11.59
Range is tight.
Plans with PA
38 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Lemborexant used for?

Lemborexant is a Orexin Receptor Antagonist medication tracked in Medicare Part D.

Is there a generic for Lemborexant?

No. Lemborexant is brand-only with no generic equivalents currently in market.

How much does my plan pay for Lemborexant?

Across 329 Part D plans, Lemborexant averages $11.58/unit (NADAC). Lowest available: $11.57/unit. Highest in distribution: $11.59/unit.

Is Lemborexant on the FDA shortage list?

No. Lemborexant is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Orexin Receptor Antagonist2 alternatives in D1
01
Daridorexant
Brand: QUVIVIQ
$16.70Lowest NADAC
0Generic mfrs
$36.5MCY24 Part D spend
Compare →
02
Suvorexant
Brand: BELSOMRA
$15.22Lowest NADAC
0Generic mfrs
$222.6MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.